Two additional Alzheimer’s disease cases without anti-GFAP autoantibodies in CSF (used as a “control”) showed complement C4d deposition only in neuritic plaques but not on astrocytes. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.